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adult-born neurons in doubly transgenic APP/PS1 mice
Abstract
The hippocampus is heavily affected by progressive neurodegeneration and beta-amyloid pathology in
Alzheimer's disease (AD). The hippocampus is also one of the few brain regions that generate new
neurons throughout adulthood. Because hippocampal neurogenesis is regulated by both endogenous and
environmental factors, we determined whether it benefits from therapeutic reduction of beta-amyloid
peptide (Abeta)-related toxicity induced by passive Abeta immunotherapy. Abeta immunotherapy of
8-9-month-old mice expressing familial AD-causing mutations in the amyloid precursor protein and
presenilin-1 genes with an antibody against Abeta decreased compact beta-amyloid plaque burden and
promoted survival of newly born neurons in the hippocampal dentate gyrus. As these neurons matured,
they exhibited longer dendrites with more complex arborization compared with newly born neurons in
control-treated transgenic littermates. The newly born neurons showed signs of functional integration
indicated by expression of the immediate-early gene Zif268 in response to exposure to a novel object.
Abeta immunotherapy was associated with higher numbers of synaptophysin-positive synaptic boutons.
Labeling dividing progenitor cells with a retroviral vector encoding green fluorescent protein (GFP)
showed that Abeta immunotherapy restored the impaired dendritic branching, as well as the density of
dendritic spines in new mature neurons. The presence of cellular prion protein (PrP(c)) on the dendrites
of the GFP(+) newly born neurons is compatible with a putative role of PrP(c) in mediating
Abeta-related toxicity in these cells. In addition, passive Abeta immunotherapy was accompanied by
increased angiogenesis. Our data establish that passive Abeta immunotherapy can restore the
morphological maturation of the newly formed neurons in the adult hippocampus and promote
angiogenesis. These findings provide evidence for a role of Abeta immunotherapy in stimulating
neurogenesis and angiogenesis in transgenic mouse models of AD, and they suggest the possibility that
Abeta immunotherapy can recover neuronal and vascular functions in brains with beta-amyloidosis.
Neurobiology of Disease
A Immunotherapy Protects Morphology and Survival of
Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice
Barbara Biscaro,1 Olle Lindvall,2,4 Christoph Hock,1 Christine T. Ekdahl,2,3,4 and Roger M. Nitsch1
1Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland, 2Laboratory of Neurogenesis and Cell Therapy, Section of Restorative
Neurology, Wallenberg Neuroscience Center, University Hospital, SE-221 84 Lund, Sweden, 3Division of Clinical Neurophysiology, University Hospital,
SE-221 85 Lund, Sweden, and 4Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, SE-221 84 Lund, Sweden
The hippocampus is heavily affected by progressive neurodegeneration and -amyloid pathology in Alzheimer’s disease (AD). The
hippocampus is also one of the few brain regions that generate new neurons throughout adulthood. Because hippocampal neurogenesis
is regulated by both endogenous and environmental factors, we determinedwhether it benefits from therapeutic reduction of-amyloid
peptide (A)-related toxicity induced by passive A immunotherapy. A immunotherapy of 8–9-month-old mice expressing familial
AD-causing mutations in the amyloid precursor protein and presenilin-1 genes with an antibody against A decreased compact
-amyloid plaque burden and promoted survival of newly born neurons in the hippocampal dentate gyrus. As these neurons matured,
they exhibited longer dendrites with more complex arborization compared with newly born neurons in control-treated transgenic
littermates. The newly born neurons showed signs of functional integration indicated by expression of the immediate-early gene Zif268
in response to exposure to a novel object. A immunotherapy was associated with higher numbers of synaptophysin-positive synaptic
boutons. Labeling dividing progenitor cells with a retroviral vector encoding green fluorescent protein (GFP) showed that A immuno-
therapy restored the impaired dendritic branching, as well as the density of dendritic spines in new mature neurons. The presence of
cellular prion protein (PrPc) on the dendrites of the GFP newly born neurons is compatible with a putative role of PrPc in mediating
A-related toxicity in these cells. In addition, passive A immunotherapy was accompanied by increased angiogenesis. Our data estab-
lish that passive A immunotherapy can restore the morphological maturation of the newly formed neurons in the adult hippocampus
and promote angiogenesis. These findings provide evidence for a role of A immunotherapy in stimulating neurogenesis and angiogen-
esis in transgenic mouse models of AD, and they suggest the possibility that A immunotherapy can recover neuronal and vascular
functions in brains with -amyloidosis.
Introduction
The pathology of Alzheimer’s disease (AD) is characterized by the
accumulation of -amyloid peptides (A), neurofibrillary tan-
gles, reactive astrocytes, and activated microglia, leading to cog-
nitive decline and dementia (Haass and Selkoe, 2007; Marcello et
al., 2008). Mouse models expressing familial AD-causing muta-
tions reproduce some of these signs, allowing for the exploration
of treatments designed to reduce the pathology (Holcomb et al.,
1998; Oddo et al., 2003; Kobayashi and Chen, 2005). A immu-
notherapy can reduce brain -amyloid and restore cognition in
such transgenic mouse models (Schenk et al., 1999; Bard et al.,
2000;Morgan et al., 2000; DeMattos et al., 2001). In patients with
AD, A vaccination cleared brain A and slowed cognitive de-
cline in a subcohort of patients (Hock et al., 2003; Nicoll et al.,
2003). Although both A clearance and stabilized cognition cor-
related with titers of anti-A antibodies, the initial clinical trial
was prematurely interrupted because of side effects, and it is cur-
rently unclear whether reducing brain A is sufficient to halt
disease progression andwhether therapeutic A clearance should
start before the onset of neurodegeneration (Hock et al., 2003;
Holmes et al., 2008). Adult neurogenesis continues throughout
life in two restricted brain regions (Altman and Das, 1965; Eriksson
et al., 1998). In the dentate gyrus, new granule cells contribute to
themaintenance of hippocampal functions, includingmood reg-
ulation, learning, and memory (Shors, 2008; Zhao et al., 2008).
Enriched environment, exercise, pharmacological compounds,
as well as stroke, epilepsy, and neurodegeneration, affect adult
neurogenesis and enhanced neurogenesis may restore functions
in neurodegenerative diseases including AD (Bengzon et al.,
1997; Kempermann et al., 1997; Parent et al., 1997; van Praag et
al., 1999; Arvidsson et al., 2002; Curtis et al., 2003; Santarelli et al.,
2003; Lie et al., 2004; Kuhn et al., 2007; Abdipranoto et al., 2008).
Initial signs for increased neurogenesis in postmortem brains
obtained from patients with AD were not confirmed by subse-
quent studies suggesting impaired maturation of new neurons
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(Jin et al., 2004; Li et al., 2008). Because aggregated oligomeric
forms of A are neurotoxic in vivo (Lesne et al., 2006; Shankar et
al., 2008), we explored whether reducing brain A by A immu-
notherapy has a protective role in adult neurogenesis in doubly
transgenic amyloid precursor protein/presenilin-1 (APP/PS1)
mice. In a prior experiment, active vaccination increased neuro-
genesis in young transgenic mice (Becker et al., 2007). It is un-
known, however, whether passive A immunotherapy can rescue
adult neurogenesis in aged transgenic mice with -amyloid-
related impairments of neurogenesis.We addressed this question
by treating 8–9-month-old APP/PS1 mice characterized by pre-
existing -amyloid pathology with weekly injections of an anti-
body against A over a 3.5 month period. We found that A
immunotherapy increased numbers of new neurons, these
showed morphological signs of synaptic activity, improved den-
dritic branching, and restored numbers of dendritic long-thin,
stubby, and mushroom spines. Moreover, A immunotherapy
increased angiogenesis in the dentate gyrus.
Materials andMethods
Animals and treatments. Heterozygous doubly transgenic mice express-
ing both human mutant APP (Tg 2576; Hsiao et al., 1996) and human
mutant PS1 (mutation: M146L) were generated by crossing heterozy-
gous Tg2576 mice on a hybrid C57BL6/J FVB/N SJL/J background,
with no obvious signs of embryonic lethality, with PS1-transgenic
mice on a hybrid Swiss Webster  B6D2 background. The APP/PS1-
transgenic mice were compared with age-matched littermates or non-
transgenic (non-tg) mice with the same hybrid background. Genotypes
were determined by PCR. Both males and females were housed in stan-
dard cages with females in groups of two to four and males single-caged
under 12 h light/dark conditions with ad libitum access to water and
food. The -A antibody used throughout these experiments is a chi-
meric monoclonal antibody consisting of human variable domains and
mouse IgG2a constant regions. It selectively recognizes with high-affinity
(low nM range) aggregated forms of A1-40 and A1-42, as well as
-amyloid plaques on tissue sections obtained fromhumanor transgenic
mouse brains. The antibody is specific for aggregated A and does not
cross-react with the unprocessed full-length APP.
In a first experiment, at 8 months of age, 14 APP/PS1mice were either
treated with -A (n  7, six males and one female) or an irrelevant
control antibody with the same isotype (IgG2) raised against bovine
herpes virus (clone 2H6-C2; European Collection of cell cultures, Ecacc)
(ct ab) (n 5; 4 males and 1 female). The antibodies were administered
once a week at a dose of 5 mg/kg i.p. for 3.5 months before perfusion. In
a second experiment, 15 mice were injected with green fluorescent pro-
tein (GFP)-expressing retrovirus into the dentate gyrus at 3 months of
age, 1 month after the beginning of either passive A immunization or
vehicle treatment; n  5 (2 males and 3 females) APP/PS1 mice with
-A treatment (5 mg/kg i.p.) and n 5 (2 males and 3 females) APP/
PS1 and n  5 (2 males and 3 females) non-tg mice with vehicle treat-
ment (PBS, 100l/10 g body weight, i.p.) for 2months before perfusion,
starting at 2 months of age. In general, after a 5 min transport from the
animal facility within the same building, mice were placed in their home
cages under a hood for 30 min before anesthesia and transcardial perfu-
sion. This procedure caused no increases in expression of the immediate
early gene Zif268 in the brains. To experimentally stimulate immediate
early gene expression, mice were exposed for 10 min to a novel object by
placing a quarter of an apple wrapped in tin foil into their home cages. All
mice intensively explored the novel object. The novel object exposure
was followed by a 10 min interval until anesthesia was initiated and
followed by an additional 15min interval until brainswere perfused. This
experimental setup resulted in the consistent appearance of Zif268 pro-
tein in discrete foci in cells throughout the brain cortex and hippocam-
pus, including the nuclei of bromodeoxyuridine-positive (BrdU)
newly born neurons in the SVZ/GCL. The presence of Zif268 protein as
early as 35min after the onset of novel object exposure is compatible with
the known time dependence of immediate early gene expression in brain
following stimulation (Richardson et al., 1992; Guzowski et al., 1999;
Kubik et al., 2007).
To exclude nonspecific effects of A immunotherapy on neurogen-
esis, we used non-tg, wild-type mice that do not express human APP or
have -amyloid pathology. These mice were treated with either vehicle
(PBS, 100l/10 g bodyweight, i.p.; n 5; 2males and 3 females) or-A
(5mg/kg i.p.; n 4; 1male and 3 females) for 10 weeks before perfusion,
starting at 2 months of age.
In the different experiments, there was a good balance between num-
bers of male and female mice, and results were, therefore, pooled. Be-
cause of low numbers of either male or female animals, a reliable
statistical comparison could not be made, but no obvious influence of
gender on any parameter of neurogenesis was detected. All experimental
procedures followed guidelines set by the Swiss veterinary cantonal office
for the use and care of laboratory animals (License Nr 48/08).
Bromodeoxyuridine labeling. Mice were injected with the thymidine
analog BrdU (50 mg/kg i.p.; dissolved in potassium PBS (KPBS)) twice
daily for 2 weeks, for labeling of mitotic cells (Dolbeare, 1995), starting 1
month before perfusion. In non-tgmice subjected to either vehicle or A
immunotherapy, BrdU (50 mg/kg i.p.; twice daily for 3 d) was injected 1
month after the beginning of the treatment.
Retrovirus-GFP labeling. An oncoretroviral vector derived from the
Moloney sarcoma virus and expressing GFP under control of the Rous
sarcoma virus promoter (MolRG) was used. Transfer vector and helper
vectors were gifts fromWolfgang Kelsch and Carlos Lois (Massachusetts
Institute of Technology, Cambridge, MA). The viral solution was prepared
by cotransfection ofHEK293FT cells (Invitrogen) using calcium–phosphate
precipitation. After 48 h, conditioned media were concentrated by two se-
quential ultracentrifugations in sucrose gradients. Viral particles were resus-
pended in sterile PBS, aliquoted, and stored at 80°C until use. Viral
concentrations (108–9 cfu/ml) were determined by serial dilutions on
HEK293FTcells, andthenumberofGFPcellswascounted48hafter infection
using flow cytometry. For labeling of the new neurons, mice were deeply anes-
thetized with ketamin/xylaxine and given unilateral injections of the retroviral
vector(1.5l at0.2l/min) into thedentategyrus(coordinates:2mmposterior
and 1.5mm lateral frombregma and 2.3mmventral from skull).
Immunohistochemistry.Mice were anesthetized with ketamin/xylaxine
and transcardially perfused with 50 ml of PBS, followed by 100 ml of
ice-cold 4% paraformaldehyde in 0.1 M PBS, pH 7.4. Brains were re-
moved, post-fixed overnight in the same medium, and put in 20% su-
crose in 0.1 M phosphate buffer for 24 h. Coronal sections (30 or 40 m
for the analyses following retrovirus injections) were cut on a sliding
microtome and stored in cryoprotective solution. For immunohisto-
chemistry, preincubation with appropriate normal sera was carried out
for 1 h at room temperature. For epitope retrieval of BrdU, phospho-
histone H3 (p-H3) and proliferating cell nuclear antigen (PCNA), free-
floating sections were denatured in 1 M HCl for 30 min at 65°C.
Primary antibodies were as follows: rabbit anti-ionized calcium-binding
adapter molecule 1 (Iba1) [a marker for microglia/macrophages (Imai et
al., 1996); 1:1000; Wako Chemicals]; rat anti-CD11b (a marker for acti-
vated microglia; 1:200; BD Pharmingen); mouse anti-human -amyloid
(6E10) (1:1000; Covance); rat anti-BrdU (1:100; Oxford Biotec); mouse
anti-neuronal nuclei marker (NeuN) (1:100; Millipore Bioscience Re-
search Reagents); rabbit anti-S100 (a marker for astrocytes; 1:5000;
SWANT); rabbit anti-C terminus of the transcription factor Zif268 [a
marker for synaptic activity (Beckmann and Wilce, 1997); 1:250 (Santa
Cruz Biotechnology)]; mouse anti-polysialic acid-neural cell adhesion
molecule (PSA–NCAM) [amarker for immature neurons (Rougon et al.,
1982); 1:2000; AbCys]; mouse anti-synaptophysin (SYN) (a marker for
synapses; 1:200; Sigma); rabbit anti-mouse glucose transporter 1 (Glut1),
a marker for glucose transporter1 highly expressed in endothelial cells of
barrier tissues such as the blood–brain barrier (1:500; AlphaDiagnostic),
goat anti-prion protein [(Hantman and Perl, 2005); 1:400; Millipore Bio-
science Research Reagents], and biotinylated–isolectin IB4 (1:200; Invitro-
gen). Isolectin–IB4 binds to microglia, group B erythrocytes, perivascular
cells, and endothelial cells and can be used to stain adult brain vasculature
(Ernst and Christie, 2006).
Free-floating sections were incubated overnight at 4°C. Secondary
antibodies for detection were Cy3-conjugated donkey-anti-rabbit/rat,
Biscaro et al. • A Immunotherapy Increases Neurogenesis J. Neurosci., November 11, 2009 • 29(45):14108–14119 • 14109
FITC-conjugated goat anti-mouse/rabbit,
Cy5-conjugated donkey anti-mouse, biotinyl-
ated anti-goat, Cy5-conjugated streptavidin
and for lectin-staining FITC-conjugated
streptavidin (all 1:200; Jackson ImmunoRe-
search Laboratories) with incubation for 2 h at
room temperature in the dark. Rinsing in
0.25% Triton X-100 was carried out between
each incubation. To detect -amyloid plaques
decorated with the antibody used for passive
immunotherapy, sections were incubated with
Cy3-conjugated donkey-anti-mouse (1:200;
Jackson ImmunoResearch Laboratories). For
single-staining with rabbit anti p-H3, specifi-
cally expressed only from late G2 interphase
until anaphase, thus providing the actual num-
ber of dividing cells (Hendzel et al., 1997) (1:
400; Upstate Biotechnology) or with mouse
anti-PCNA [expressed in early G1 and S phases
(Bravo and Macdonald-Bravo, 1987); 1:200;
Santa Cruz Biotechnology], avidin–biotin per-
oxidase complex (Elite ABC kit; Vector Labora-
tories), 3,3-diaminobenzidine and hydrogen
peroxide were used. Chromogenic visualiza-
tion included pretreatment with blocking of
endogenous peroxidase activity with 3%H2O2
and 10% methanol. Sections were mounted
on chrom-gelatin-coated microscope slides
(Super-frost-plus; Menzel) and coverslipped
with aqueous anti-fading mounting medium
(PVA–DABCO). Thioflavin-S (ThioS) stain-
ing for fibrillar A was done as described pre-
viously (Schmidt et al., 1995). In short, floating
sections from APP/PS1 mice were washed in
KPBS and mounted on chrom-gelatin-coated
glass slides before being processed. After treat-
ment for 10 min with 0.25% potassium per-
manganate, sections were washed in KPBS and
incubated in 1% potassium metabisulfite and
1% oxalic acid until they appeared white. Sec-
tions were then floated 3 s in 0.25% acetic acid,
washed in water and stained for 5 min with a
solution of 0.015%Thio-S in 50% ethanol. Finally, sections were washed
in 50% ethanol and in water, then dried, and coverslipped with PVA–
DABCO. For Prussian blue staining for hemosiderin, whose presence is
an indication of a past microhemorrhage event, sections were mounted
on coated slides and then stained with equal solutions of 20% HCl and
10% potassium ferrocyanide [K4Fe(CN)6*3H2O] in water for 30 min at
37°C. All chemicals were from Sigma. Control stainings included omis-
sion of the primary antibody and/or use of different tissues known to be
positive for the specific antibody (e.g., tonsils for p-H3 and hippocampus
from young mice exposed to novel enviroment for Zif268).
Stereology andmicroscopic analyses.Allmeasurements were performed
by an observer blind to animal identifications. Immunohistochemical
stainings were examined with an Inverted Leica DM IRE2 fluorescence
and light microscope. Numbers of immunoreactive cells were counted
bilaterally in the granule cell layer (GCL), and within one cell diameter
below this region in the subgranular zone (SGZ), throughout the entire
dentate gyrus. Stereological estimations of the total number of BrdU
and PSA–NCAM in the SGZ/GCL, as well as numbers of Glut1 and
IsolectinB4 blood vessels in the dentate gyrus, were performed using
the optical fractionator method (Gundersen and Jensen, 1987; West et
al., 1991). Six to eight coronal sections were analyzed per animal using
the Leica DM4000B microscope with a 100 oil objective, Olympus
DP71 color digital camera, and newCAST software (Visiopharm). For
systematic sampling, the frame area was set to 3590m2with a sampling
interval of 226 m at the x and y level, and the optical dissector consti-
tuting a 15-m-thick fraction of the total section thickness (measuring
22–25m after processing). Neither the area for counting nor the thick-
ness of the analyzed sections differed between groups, which allowed for
comparisons of cell counts. The SGZ/GCL and dentate hilus volumes
were measured using the same stereological equipment in the same sec-
tions. The intersections ofNeuN-stained dentate gyri with a digitally over
Figure 1. A immunotherapy attenuated-amyloid pathology. A, B, Immunohistochemical staining of brain tissue sections
obtained from APP/PS1 mice treated with A immunotherapy (-A) or a control antibody (ct ab) with a Cy3-conjugated
antibodydirectedagainstmouse IgG revealedbindingof the therapeutic antibody to-amyloidplaques (B), an indication that the
antibody had crossed the blood–brain barrier and reached the brain. CX, Cortex; CC, corpus callosum; LSI, lateral septal nuclei.C,D,
Representative ThioS staining of compact -amyloid plaques. CX, Cortex; DG, dentate gyrus; the dotted lines depict the corpus
callosum (CC). Therewas a significantly lower area fraction of ThioS-positive-amyloid plaques in APP/PS1mice treatedwith A
immunotherapy (1.14 0.14% area) compared with control antibody-treated mice (1.75 0.16% area; p 0.05; unpaired t
test). Scale bars: (in A and B) 500m; (in C and D) 250m.
Table 1. Morphological phenotypes of Iba1 plus microglia and area fraction for
CD11b plus activatedmicroglia in APP/PS1 doubly transgenic mice subjected to
A immunotherapy
Region Microglia type/Area fraction Control antibody A Immunotherapy
SGZ/GCL % ramified Iba1 36.4 22.5 24.4 4.9
% intermediate Iba1 49.3 3.3 57 4.8
% amoeboid Iba1 13 2.9 15.5 2.7
% round Iba1 1.3 0.5 3.2 1.4
Hilus % ramified Iba1 20.5 2.9 12.4 3.0
% intermediate Iba1 57.7 7.2 59.8 3.4
% amoeboid Iba1 13.7 4.2 21.5 4.7
% round Iba1 3.3 1.1 6.3 1.1
Septum % ramified Iba1 18.3 3.3 17.7 3.4
% intermediate Iba1 57.7 7.2 49.8 3.7
% amoeboid Iba1 15.4 5.3 21.4 2.9
% round Iba1 8.6 3.2 11.1 2.7
Hippocampus % area CD11b 0.50 0.10 0.65 0.11
Septum % area CD11b 0.84 0.20 0.98 0.31
Morphological subtypes of Iba1 plus microglia: ramified and intermediate represent quiescent and amoeboid and
round represent activatedmicroglia. No significant differenceswereobservedbetweengroups. Values aremeans
SEM; n 5 (control antibody) and n 7 (A immunotherapy).
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imposed counting grid were counted in 8–10 coronal sections with a 40
objective. Amaximumof 150–200 intersecting points (area per point: 0.078
mm2) were counted per animal, and the volume was estimated apply-
ing Cavalieri’s principle (Gundersen et al., 1988). Because of their small
numbers, all p-H3, BrdU, and PSA–NCAM cells in the SGZ/GCL
were counted in each section. Colocalization of up to 50 double- or
triple-stained BrdU cells with NeuN/S100/Zif268 was validated using
a confocal scanningmicroscope (Leica TCS/SP2; Leica) with Argon laser
488, HeNE laser, 568 and 633 excitation filters. Numbers of blood vessels
bilaterally in the entire dentate gyrus of antibody-treated APP/PS1 mice
were estimated as described elsewhere (Lee et al., 2005) using the same
stereological settings as described above.Briefly, the total numberof branch-
ingpoints (defined as the point inwhich a single capillary branches into two,
forming aY)was countedusing theoptical dissector. If these points are set as
the counting targets, twice this number is equal to the number of capillary
segments. Since thickverticaluniformrandomsectionswereused, the length
of blood vessels was estimated via counting the intersections between capil-
laries and “virtual” isotropic planes projected through the section by
computer-assisted stereology (Larsen et al., 1998). SYN-positive presynatic
terminals were counted bilaterally in themolecular layer (ML) of three hip-
pocampal sections using a Leica DM4000B microscope with a 100 oil
objective, OlympusDP71 color digital camera, and newCAST software (Vi-
siopharm) with frame area set to 250m2, with 200m sampling intervals
at the x and y levels, andwith the optical dissector constituting 2.5-m-thick
fractions of the total section thickness.
The morphology of Iba1microglia in the dentate gyrus and septum
was characterized as ramified, intermediate, amoeboid or round profile,
as described elsewhere (Thored et al., 2009),
and the percentage of the respective phenotype
was calculated over the total number of Iba1
cells considered (90 cells).
Morphological analysis of new immature neu-
rons. To determine dendrite length and
branching, PSA–NCAM cells (n  40 from
each group) were analyzed using a Leica
DM4000 microscope with a 63 water objec-
tive and a digital zoom of 2. On average, 50–60
Z-seriesof0.25mweremerged foranalysis.The
measurements were done by using NeuronJ
(http://www.imagescience.org/meijering/software/
neuronj/).
NeuronJ is an ImageJ plugin module devel-
oped for tracing and quantification of elon-
gated structures in two-dimensional images, in
particular neurites in fluorescence microscopy
images.
Morphological analysis of new mature neu-
rons. Following retrovirus injection, the den-
dritic length and branching of 5-week-old
GFP new granule cells (n  15/group) were
analyzed using the Leica DM4000 microscope
with 20water objective and a digital zoom of
2 (1024 1024 pixel). On average, 50–70 pic-
tures with 0.5 m steps were merged for anal-
yses. High-magnification pictures for spine
density analysis were also taken using the Leica
DM4000microscope with 63water objective
and a digital zoom of 6 (512  512 pixel). On
average, 100–130 pictures of 0.120 m steps
were merged for analysis. The autofluores-
cence of the labeled neurons was sufficiently
strong so that anti-GFP staining was unneces-
sary. Z-stacks were deconvoluted, a process
that filters the signal to improve the clarity of
images by increasing resolution, removing out-
of-focus blur and eliminating noise, using the
open source Huygens remote manager (http://
hrm.sourceforge.net/). Three-dimensional re-
constructions of deconvoluted z-stacks were
performed with Imaris 6.1 (Bitplane). After
three-dimensional reconstructions, Scholl analysis, in which intersec-
tions between dendrites and concentric circles were counted, each one
with a 10m increment from the previous and centered at the soma, to
determine the total dendrite length and branching density, or spine
classification (stubby, long-thin and mushroom according to the
original classification of Peters and Kaiserman-Abramof, 1970) along
40 m segments (n 50/group) were done using the aforementioned
software and its MatLab extensions (ImarisXT). Because spine den-
sity increases proportionally to the distance from the cell body, for
each GFP neuron used in the Scholl analysis, one to two dendritic
segments were analyzed in the medial and external part of the outer
ML, respectively.
Image analysis.All images were subjected to the following transforma-
tions: color pictures were first converted to grayscale images (8-bit), and
the resulting images were then further adjusted to black and white by
defining a grayscale cutoff point (threshold), and finally, all pictures
within each experimental group were adjusted to the same threshold to
allow for comparison of results. Quantifications of diffuse plaque load
(6E10 staining), compact plaque burden (ThioS), and cerebral amyloid
angiopathy (CAA) measured in the ThioS staining, were performed as
described elsewhere (Wilcock et al., 2006). Briefly, ImageJ was used for
measuring the area fraction (% area), defined as the area positive for the
staining in a constant and determined area, in cortex, hippocampus, and
thalamus of both hemispheres. Similarly, ImageJ was used to quantify
Iba1 immunoreactivity: in the dentate gyrus, the number of Iba1 cells
was electronically counted, whereas in broader cerebral regions, e.g.,
Figure 2. A immunotherapy increased neurogenesis and dendritic arborization of newly born neurons in 11–12-month-old
APP/PS1mice. A immunotherapy significantly increased numbers ofmature BrdU/NeuN; this increasewas accompanied by
a trend for higher numbers of immature PSA-NCAM neurons (APP/PS1ct ab: 306 31 vs APP/PS1-A: 452 42
BrdU/NeuN cells; p 0.05; and APP/PS1ct ab: 219 79 vs APP/PS1-A: 842 275 PSA-NCAM cells; p 0.06).
A, B, Representative low-magnification images of PSA-NCAM neurons in the dentate gyrus of control-treated (A) and A
immunotherapy-treated (B)mice. A immunotherapy significantly increased thenumber of dendrites of PSA-NCAMneurons in
APP/PS1 mice and the length of dendrites of PSA-NCAM neurons in APP/PS1 mice (number of dendrites per cell: APP/PS1ct
ab: 2.45 0.3 vs APP/PS1-A: 4 0.4; p 0.01; and length of dendrites: APP/PS1ct ab: 54.4 7 vs APP/PS1-A:
85.510m;p0.01).C,D, High-magnification confocal details, including corresponding computer renderings resulting from
quantitative NeuronJ analyses of the cells shown in the yellow squares in A and B, respectively, taken from comparable regions
within the dentate gyrus. Scale bars: A, 60m; C, 20m. N 40 cells were analyzed per group. Unpaired t test.
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lateral septal nuclei, fornix, and thalamus, the area fraction positive for
Iba1 staining was evaluated. The same analysis was used to quantify
CD11b areas in the hippocampus and septumas ameasure ofmicroglia
activation. Assessment of the SYN levels was performed in the frontal
neocortex and the hippocampal outer ML (Buttini et al., 2005; Priller et
al., 2006). For each zone of interest, four confocal images were taken at
magnification 63 in water with digital zoom 2, with z-stacks of 0.25
m.Aftermaximum intensity projection of z-stacks, the digitized images
were analyzed for the signal intensity (average pixel intensity) of SYN-
labeled structures by using ImageJ. For the histological analysis of the
colocalization of cellular prion protein (PrP c) on dendrites of GFP
newly born neurons, high-magnification stacks (63 z8; 512  512
pixel; 0.16 z-step) were analyzed by using ColocImaris software. This
software specifically identifies voxels that are positive in both fluores-
cent channels, thereby dramatically reducing artifacts generated by
overlays in z-levels.
A ELISA. Blood was withdrawn by heart puncture after deep anes-
thesia with ketamin/xylazine directly before perfusion and separated
from erythrocytes by centrifugation. Plasma A1-42 was measured with
the INNOTEST -Amyloid (1-42) ELISA kit (Innogenetics) using the
“high sensitivity” conjugate.
Statistical analyses. Comparisons between animal groups were per-
formed using unpaired Student’s t test or one-way ANOVA, followed by
Bonferroni’s or Fisher’s least significant difference post hoc tests. Data are
presented as mean SEM. Differences are considered significant at p
0.05. Calculations were made with Statview 5.0.
Results
Passive A immunotherapy attenuated -amyloid pathology
in APP/PS1-transgenic mice
After 3.5 months of treatment of 8–9-month-old doubly trans-
genic APP/PS1micewithweekly i.p. injections of-A, the high-
est accumulation of antibody was present in septum, fornix, and
thalamus, as indicated by specific Cy3 anti-mouse IgG antibody
staining (Fig. 1A,B). Antibodywas also detected at lower concen-
trations within the hippocampus. The reasons for differences in
antibody concentrations throughout the brains may include
region-specific variations of extraction rates or varying amounts
of CAA influencing both delivery and extraction rates of the an-
tibody. Another possibility is a concentration gradient of antibody
surrounding potential sites of entry into the brain, including the
choroid plexus and the lateral ventricles. Fixation artifacts are likely
excluded, because all brains were perfused with fixative before im-
munohistochemical analyses. In general, the antibody was associ-
ated with amyloid deposits, if present.
At1 year of age, the APP/PS1 mice treated with the control
antibody presented severe -amyloid deposits throughout their
brains including the dentate gyrus as well as some deposits in the
GCL. In addition, these mice developed CAA in cortex and thal-
amus. Although the antibody treatment did not change the 6E10-
immunopositive A burden (data not shown), the amount of
-amyloid plaques detected by ThioS staining in the whole brain
was significantly reduced by 37.8% in -A compared with ct
ab-treated mice (APP/PS1ct ab: 1.75  0.16 vs APP/PS1-
A: 1.14 0.14% area; p 0.05) (Fig. 1C,D). In the hippocam-
pus, the area fraction covered with ThioS -amyloid plaques
in antibody-treated APP/PS1 mice was 	60% lower, from
1.32  0.29% in vehicle-treated APP/PS1 animals to 0.48 
0.21% ( p 0.05) in -A-treated mice. Progressive accumula-
tion of -amyloid in the vicinity of blood vessels can result in
microhemorrhages, and some studies have linked immunother-
apy to an initial increase in CAA and microhemorrhages (Pfeifer
et al., 2002; Wilcock et al., 2004a; Racke et al., 2005), followed by
Figure 3. Newborn BrdU neurons expressed the activity-dependent immediate early gene Zif268 during A immunotherapy as a sign of functional integration in pre-existing hippocampal
synaptic circuits. Immunohistochemical stainings for the immediate-early gene product Zif268 (green), BrdU nuclei (red), NeuN neuronal nuclei (blue), overlay of the three channels (merge),
and confocal orthogonal projections of merged Zif268 and BrdU images of selected granular neurons (ortho). A–D, Background expression of Zif268 in untreated APP/PS1 control mice without
exposure to novel object stimulation: absent localization of Zif268 in nuclei of BrdUgranular neurons. E–H, Presence of Zif268 in BrdUnuclei of granular neuronswithin the SGZ/GCL in response
to novel object exposure in vehicle-treated APP/PS1 mice. I–M, Presence of Zif268 in BrdU nuclei of granular neurons within the SGZ/GCL during A immunotherapy and in response to novel
object exposure. Circles depict selected BrdU cells to facilitate their identification in the Zif268 staining. Scale bar: A, 10m.
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decrease during longer treatment periods (Schroeter et al., 2008).
To exclude that the -A antibody treatment used here de-
creased parenchymal A plaques but increased vascular A de-
posits, we quantifiedCAAvisualized byThioS staining.However,
no differences were detected between treatment and control
groups (APP/PS1ct ab: 0.21 0.09 vs APP/PS1-A: 0.17
0.09% area). The presence of microhemorrhages was detected by
Prussian blue staining of hemosiderin. We observed microhem-
orrhages in 26% of the immunotherapy-treated APP/PS1-
transgenic mice compared with 60% in ct
ab-treated mice (2: NS) indicating the
absence of increased microhemorrhages
during A immunotherapy in our exper-
imental setting. Reductions in -amyloid
plaque load were not accompanied by in-
creased plasma levels of A42 (APP/
PS1ct ab: 1413.5  96.6 pg/ml vs APP/
PS1-A: 1753  193.9 pg/ml). To
explore whether microglia could be in-
volved in the reduction of -amyloid
plaques (Schenk et al., 1999), we evaluated
the morphology and counted numbers of
Iba1-positive cells. The -A- and ct ab-
treated mice showed similar numbers of
Iba1 cells in the dentate gyrus (SGZ/GCL:
APP/PS1ct ab: 50.58.6vsAPP/PS1-
A: 57.3 6.4 cells; hilus: APP/PS1ct ab:
50.8  14.4 vs APP/PS1-A: 55.9  7
cells; septum-fornix-thalamus: APP/PS1
ct ab: 7.4 1.02 vs APP/PS1-A: 8.9
1.06% area). There was no difference
between the groups in the percentage of
ramified-, intermediate-, amoeboid- or
round-shaped Iba1 microglia in the den-
tate gyrus or in the septum (Table 1). Fur-
thermore, measurement of areas in the
hippocampus and in the septum immuno-
reactive (CD11b) for activated microglia
did not reveal any differences between
groups (Table 1). Microglia can increase
theirproliferation rateduringchanges inac-
tivation state, but numbers of BrdU/
Iba1 cells in the SGZ/GCL did not differ
between-A andct ab-treatedmice (APP/
PS1ct ab: 20.2 2.1 vs APP/PS1-A:
21.6 2.7). Also, no significant differences
wereobserved inSGZ/GCLorhilarvolumes
(SGZ/GCL: APP/PS1ct ab: 2.6  0.6 vs
APP/PS1-A: 3.60.2mm3;hilus:APP/PS1ctab:3.30.2vs
APP/PS1-A: 3.4 0.2 mm3).
Passive A immunotherapy increased neurogenesis
and dendritic arborization of new immature neurons in
APP/PS1-transgenic mice
In the APP/PS1 mice used in these experiments, the pathology
associates with 50% more proliferating cells (p-H3 and
BrdU) than non-tg controls.However, in the same animals, this
initial increase does not result in higher numbers of mature
(BrdU/NeuN) nor immature (PSA–NCAM) neurons, sug-
gesting that the progenitors may not survive the A-related tox-
icity (B. Biscaro, unpublished observations; Chen et al., 2008).
We first tested whether the antibody-mediated reduction in
-amyloid pathology had reversed these impairments of neuro-
genesis. Interestingly, both the numbers of BrdU/NeuN new
mature neurons (APP/PS1ct ab: 306 31 vs APP/PS1-A:
452  42 cells; p  0.05) and PSA–NCAM young neurons
(APP/PS1ct ab: 219 79 vs APP/PS1-A: 842 275 cells;
p  0.06) were higher in the -A- compared with the ct ab-
treated APP/PS1 mice. Moreover, the PSA–NCAM neurons in
the-A-treated APP/PS1mice had higher dendritic complexity
with more and longer dendrites (number of dendrites per cell:
APP/PS1ct ab: 2.45 0.3 vsAPP/PS1-A: 4 0.4, p 0.01;
Figure 4. A immunotherapy increased the number of SYN-positive boutons in theML of the hippocampus.A,B, SYN-positive
synapses in the hippocampal outer ML from controls (ct ab; A) and A immunotherapy-treated APP/PS1 mice (B). Dotted lines
depict the area analyzed stereologically for quantification of SYN-positive boutons. Arrowheads show the presence of-amyloid
plaques. C, D, High magnification details of the yellow squares in A and B, respectively. The arrowhead in C depicts dystrophic
boutons around a-amyloid plaque. Stereological quantification of SYN-positive boutons in theML revealed higher SYN levels in
A immunotherapy-treatedmice (APP/PS1ct ab: 1.40.3 vsAPP/PS1-A: 2.80.2 SYNboutons (10 6);p0.01;
unpaired t test). Scale bars: A, 120m; C, 20m.
Table 2. Effects of A immunotherapy on cell genesis in dentate gyrus of
4month-old non-tg, wild-typemice
Staining Vehicle A Immunotherapy
BrdU/NeuN 2466 260 2231 657
BrdU/S100 29.5 21 61 52
PSA–NCAM 5698 1689 5702 681
PCNA 49.2 6.4 38.4 4.8
GFAP 8797 1964 7433 1194
Iba1 3097 497 3818 355
CD11b 0 0
Markers: BrdU/NeuN and PSA–NCAM for neurogenesis; BrdU/S100 for gliogenesis; PCNA for cell proliferation; and
GFAP, Iba1, and CD11b for neuroinflammation. Values represent stereological cell counts and are means SEM;
n 5 (vehicle) and n 4 (A immunotherapy). No significant differences between groups were observed.
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and length of dendrites: APP/PS1ct ab:
54.4  7 vs APP/PS1-A: 85.5  10
m, p  0.01) (Fig. 2A–D). The number
of BrdU/S100 astrocytes did not dif-
fer between the groups (APP/PS1ct ab:
56  12.13 vs APP/PS1-A: 43 
12.72). Also the numbers of p-H3 and
BrdU, proliferating cells in the SGZ/
GCLwere similar in the two groups (APP/
PS1ct ab: 174.4  92 vs APP/PS1-
A: 210.3  45.4 p-H3 cells and APP/
PS1ct ab: 547.2 57.5 vs APP/PS1-
A: 676.6  83.4 BrdU cells). Synaptic
activity in the dentate gyrus induces ro-
bust expression of the immediate early
gene Zif268 (or Erg-1), which is essential
for the formation of long-term memories
(Jones et al., 2001). If not exposed to stim-
ulation such as novel environment or
LTP, Zif268 is not constitutively tran-
scribed in the GCL (Davis et al., 2003;
Bruel-Jungerman et al., 2006). We ana-
lyzed Zif268 expression in the SGZ/GCL
following a physiological stimulus in-
duced by a novel object (“activation”)
(Fig. 3). Without exposure to the activa-
tion stimulus, there was no Zif268 expres-
sion in APP/PS1 mice (Fig. 3A–D). The
activation stimulus induced Zif268 expres-
sion throughout theneuronal population in
the SGZ/GCL both in vehicle-treated (Fig.
3E–H) and A immunotherapy-treated
mice (Fig. 3I–L).We established that alsonew
mature neurons in A immunotherapy-
treated mice responded to the activation
stimulus as a sign of functional integration
by showing stimulus-evoked Zif268 expres-
sion in BrdU/NeuN cells (Fig. 3I–L).
Both active and passive A-immun-
izations were reported to prevent synaptic
degeneration in the frontal cortex and hip-
pocampus of transgenic mice expressing
APP mutants (Buttini et al., 2005). Consis-
tent with these findings, -A-treatedmice
showed increased numbers of SYN-positive
Figure 5. A immunotherapy increased dendritic branching and spine densities of mature retrovirally labeled newly born
neurons. A–C, Representative confocal pictures of GFPmature new neurons in the three groups of the study. Scale bar, 60m.
D, Scholl analysis of new mature granule cells labeled with retrovirus expressing GFP revealed lower dendritic complexity in
APP/PS1mice comparedwith non-tgwild-typemice and restored dendritic complexity in APP/PS1mice during A immunother-
apy comparedwith vehicle-treatedAPP/PS1mice. The graph represents themeannumber of intersections betweendendrites and
concentric radii, centered at the cell body, as a function of distance from the soma; n 15 cells/group. Error bars represent SEM
4
p 0.05 non-tg versus APP/PS1, and APP/PS1 versus APP/
PS1 treatedwith-A.E, Representative high-magnification
segments from dendrites of new mature neurons in non-tg,
vehicle-treated APP/PS1, and -A-treated APP/PS1 mice.
Scale bar, 10 m. F–H, Computer-assisted classification of
spines along 40 m segments detected differences in the
number ofmushroom, long-thin, and stubby spines. F, Signif-
icant reduction of numbers of mushroom spines in APP/PS1
compared with non-tg mice and significant rescue during A
immunotherapy. G, Significant reduction of numbers of long-
thin spines in APP/PS1 comparedwith non-tgmice and signif-
icant rescue during A immunotherapy. H, Significant
reduction of numbers of stubby spines in APP/PS1 compared
with non-tg mice and a trend ( p 0.07) toward rescue dur-
ing A immunotherapy. N 50 segments/group. Error bars
represent SEM p  0.05, p  0.01, p  0.001.
ANOVA, followed by Bonferroni post hoc tests.
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boutons detected by stereological counting in the ML of the dentate
gyrus, inwhichgranulecellsextendtheirdendrites towardtheperforant
path (APP/PS1ct ab: 1.4 0.3 vs APP/PS1-A: 2.8 0.2 SYN
boutons ( 106), p  0.01) (Fig. 4A–D). Also, computer-assisted
analysis of SYN intensity in the ML revealed a significant increase
following the A immunotherapy (APP/PS1ct ab: 21.8 2.0 vs
APP/PS1-A: 35.8 3.0 staining intensity; p 0.05).
Toexcludenonspecific effectsof theA immunotherapyonneu-
rogenesis, we administered the antibody to 4 months old non-tg
wild-typemice. As expected, the numbers of new cellswere substan-
tially higher than in the oldermice. TheA immunotherapy did not
induce any significant changes innumbersofproliferatingordifferen-
tiating cells in wild-type mice (Table 2). These data indicate that
binding of the antibody to human A aggregates, rather than
nonspecific effects of IgG2, mediated the effects of A immuno-
therapy on neurogenesis in the dentate gyrus. Likewise, quantifica-
tion in the dentate gyri ofmarkers for gliogenesis, proliferation, and
neuroinflammationdidnot reveal anydifferences between antibody
and vehicle treatments of non-tg wild-type mice (Table 2).
Passive A immunotherapy restored dendritic branching and
spine density andmorphology of newmature neurons in
APP/PS1-transgenic mice
To investigate whether A immunotherapy affects the dendritic
morphology of the new granule cells also when they have matured,
we repeated the -A treatment in mice
that received retroviral injections into the
dentate gyrus to label dividing cells with
GFP. TheGFP granule cells were analyzed
5 weeks after the injection, a survival time
considered to be sufficient for the newly
born neurons to mature (van Praag et al.,
2002; Zhao et al., 2006). We observed that
the dendritic arborizations of the GFP,
new, and mature granule cells were signifi-
cantly fewer in dentate gyri of vehicle-
treated APP/PS1 mice, whereas the
numbers in-A antibody-treatedmice re-
sembled those of new neurons born in
non-tg mice (Fig. 5A–D). Spines are the
principal sites of excitatory synaptic trans-
mission and can be classified according to
their shapes and appearance. We classified
spines as proposed by Peters and
Kaiserman-Abramof (1970). “Long-thin”
spines have a total length greater than the
neck diameter; “stubby” spines are short
and wide, whereas “mushroom” spines
have a thick neck and a large irregular head.
We found significant reduction in all three
spine subgroups on GFP cells in ct ab-
treated APP/PS1 mice compared with
non-tg mice. The -A treatment reversed
this loss of spines by 50% for long-thin,
stubby, andmushroom spines (Fig. 5E–H).
Passive A immunotherapy increased
angiogenesis in dentate gyrus of
APP/PS1-transgenic mice
To explore the previously described close
links between neurogenesis and angiogene-
sis in the stem cell niche (Palmer et al.,
2000),wedeterminedwhether the enhance-
ment of neurogenesis inAPP/PS1 treatedwith passiveA immuno-
therapy was associated with increased angiogenesis. Following the
treatment,manyBrdU cellswere located adjacent to blood vessels,
and numbers of blood vessels, quantified by endothelial stains for
lectin andGlut1,were significantly higher in-A-treatedAPP/PS1
mice compared with control antibody-treated mice (APP/PS1ct
ab: 5991 384 vs APP/PS1-A: 8978 766 blood vessels; p
0.01) (Fig. 6D). Stereological estimation of vessel length detected a
trend toward an increase following antibody treatment (APP/
PS1ct ab: 0.17  0.03 vs APP/PS1-A: 0.31  0.06 m; p 
0.07).Combining theThioS staining ofCAAwith theGlut1 staining
of endothelial cells often showed disruption of Glut1 immunoreac-
tivity in the presence of ThioS-stained CAA around vessels (Fig.
6A–C), indicating that progressive accumulation of compact
-amyloid leads to the deterioration of endothelial tissues. Prevent-
ing or delaying this deposition by passive A immunotherapy may
reverse this effect and result in higher numbers of blood vessels, as
described above. Together, these findings indicate that passive im-
munotherapy can lead to increased angiogenesis as well as
neurogenesis.
Localization of cellular prion protein on dendrites of newly
born neurons
A possible role for PrPc in mediating synaptic toxicity of A oli-
gomers was described recently (Lauren et al., 2009). To explore
Figure 6. A immunotherapy increased angiogenesis in the dentate gyrus. Stereological estimation of the number of blood vessels
indicated significant increases in thenumberofbloodvessels inAPP/PS1miceduringA immunotherapy (APP/PS1ct ab: 5991384
vsAPP/PS1-A: 8978766bloodvessels;p0.01; unpaired t test).A,B, Confocal imagesof ThioS-A-deposits along thewall
of blood vessels in the cortex. C, Disruption of Glut1 expression in the presence of congophilic amyloid angiopathy. Arrowdepicts colocal-
ization of Awith Glut1, excluding the possibility that Glut1 was present but not detected because of epitope-masking by-amyloid.
D,Glut1-stainedbloodvessels(blue)andBrdU(red)inthedentategyrus:manyBrdUcellsarelocatedinthevicinityofbloodvessels.Glut1
receptor is expressedathighest levels in theendothelial cells of barrier tissues suchas theblood-brainbarrier. Dotted lines inAdepict SGZ.
Scale bars:A, 40m;D, 70m.
Biscaro et al. • A Immunotherapy Increases Neurogenesis J. Neurosci., November 11, 2009 • 29(45):14108–14119 • 14115
whether PrPc is present on retrovirus-labeled,
GFP new neurons, we analyzed colocaliza-
tion of PrPc with GFP by using ColocImaris
softwareonhigh-magnificationimagestospe-
cificallyidentifycolocalizedproteinsandtoex-
clude overlay artifacts. As expected, PrPc was
present ubiquitously on cells throughout the
brain. PrPc was also present, at equal levels
comparedwithpre-existing brain cells, on the
dendrites of retrovirus-labeled, GFP newly
born neurons. PrPc staining on dendrites of
newly born neurons had a patchy appearance
consistentwith its knowncellular distribution
(Hantman and Perl, 2005), and5% of the
analyzeddendritic surface of newly bornneu-
ronswas costained for PrPc (Fig. 7). PrPc was
present at equal levels on dendrites of newly
born neurons in both non-tg, wild-type, and
APP/PS1 mice, suggesting that the expres-
sion of the APP and PS1 transgenes under
the control of the PrPc and PDGF pro-
moters, respectively, did not affect the colocalization of PrPc with
dendrites of newly born neurons. A immunotherapy had no obvi-
ous effect on the colocalization of PrPcwith dendrites of newly born
neurons.
Discussion
The results of this study establish that reductions in compact
-amyloid plaque load in adult APP/PS1 doubly transgenic mice
by passive A immunotherapy rescue impairments in adult hip-
pocampal neurogenesis. Following A immunotherapy, more
new neurons survived, and their morphological deficits were re-
versed. Although the untreated transgenic APP/PS1 mice exhib-
ited abnormalities in dendritic branching and lower numbers of
all spine subtypes in the new hippocampal neurons, the mice
treated with A immunotherapy had longer dendrites, andmore
complex dendritic arborization with restored stubby, mush-
room, and long-thin spines. The morphology of the newly born
hippocampal neurons in transgenic mice subjected to A immu-
notherapy resembled that in untreated non-tg mice consistent
with the possibility of rescued synaptic structures. These results
were likely related to the specific interaction of the antibody with
humanA aggregates deposited in brains of APP/PS1mice—and
possibly to the lowering of -amyloid pathology—rather than to
nonspecific effects of the antibody, as indicated by the absence of
stimulated neurogenesis in the dentate gyrus of antibody-treated
non-tg, wild-type mice.
The stimulation of neurogenesis and the improved dendrite
and spine morphology of the new neurons could be related
to a more favorable microenvironment created by antibody-
related neutralizing events and the reduced neurotoxicity. In line
with this interpretation, passive A-immunotherapy amelio-
rates synaptic deficits on already formed, mature hippocampal
and cortical neurons (Buttini et al., 2005).Moreover, the formation
of newhippocampal neurons in APP-transgenicmice is increased
by active A vaccination (Becker et al., 2007). In these mice,
preventive active vaccinations with A-related antigens were ini-
tiated before the onset of -amyloid plaque formation, and the
immune responsewas then boosted	8–9months. Comparedwith
the study of Becker et al. (2007), we report here the following novel
observations: First, we demonstrate that A-immunotherapy im-
proves neurogenesis in adult animals with substantial pre-existing
-amyloid pathology, more closely resembling the stage of pathol-
ogy in human patients with a clinical diagnosis of probable AD.
Second, we show that active vaccination associated with stim-
ulation of cellular immunity is not necessary to increase neu-
rogenesis in vivo but that humoral immunity induced by
passive antibody transfer is sufficient. Third, we provide the
first experimental evidence that A immunotherapy not only
enhances hippocampal neurogenesis but also reverses deficits
in the morphological development of the new neurons. Be-
cause we found that the effects on neurogenesis were achieved
in the presence of considerable amounts of A in the brain,
our data indicate that already the initial phase of antibody-
mediated -amyloid clearance is associated with beneficial
therapeutic effects.
The involvement of adult hippocampal neurogenesis in learn-
ing and memory is still unclear, but a growing body of evidence
supports a roleof thenewneurons inmemoryacquisition (Snyder et
al., 2005; Kee et al., 2007; Jessberger et al., 2009). If the birth of
new granule cells in the SGZ/GCL leads to their recruitment into
preexisting neuronal circuits contributing to hippocampal func-
tions related to learning (Kempermann, 2008), it is conceivable
that the up-regulation of neurogenesis reported here may be re-
lated to the reversal of cognitive deficits. In support, restored
behavior in transgenic mice treated with A immunotherapy has
been observed after both active vaccination and passive antibody
transfer (Janus et al., 2000; Morgan et al., 2000; Dodart et al.,
2002; Chen et al., 2007). We found that new granule cells exhib-
ited expression of the activity-dependent immediate early gene
Zif268 (Egr-1). BecauseZif268 expression is up-regulated by neu-
ronal activity, this result is consistent with functional integration
of the new neurons into pre-existing neural circuitries.
Dendritic spines are the major sites for excitatory synaptic
input. Although large stubby spines and mushroom spines are
stable and required for the maintenance of synapses, small, long-
thin spines are unstable and thought to be required for memory
acquisition (Kasai et al., 2003). The numbers of all types of den-
dritic spines were increased during A immunotherapy. To-
gether with the longer dendrites and more ramified dendritic
arborizations, these findings are indicative of better functional
integration of the new neurons in treated compared with un-
treated transgenic mice. In support of this possibility, stereologi-
cal estimation of SYN-positive boutons in the area in which the
dendrites of the new neurons receive synaptic inputs from the
Figure 7. Expression of cellular prion protein (PrP c) on the dendrites of newly born neurons. A, Colocalization analysis of PrP c
(red) with the GFP dendrites (green) and overlay (yellow) by ColocImaris software. Inset, Maximum projection of this image
stack. B, Three-dimensional reconstruction using Imaris Surpass of both PrP c and GFP channels shows the broad presence of PrP c
on brain cells along with its colocalization on the dendrites of newly born neurons. Scale bar, 4m.
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perforant path, the dentate outer ML, revealed increases following
A immunotherapy. Spinedensities aswell asdendritic arborization
and length of newly born neurons were already decreased in
4-month-old APP/PS1 before the onset of -amyloid plaque depo-
sition in thedentategyrus consistentwith thepossibility that smaller,
oligomeric A species mediated the impairment. As a corollary, the
rescue duringA immunotherapymay also be related to neutraliza-
tion of oligomeric A species by the antibody reacting with A
aggregates.
Our data also show that A immunotherapy increased the
numbers of blood vessels in APP/PS1 doubly transgenic mice
compared with control-treatedmice.More numerous blood ves-
sels may be related to increased neurogenesis by creating niches
for the new cells. It is known that increased angiogenesis can
stimulate neurogenesis via vascular endothelial growth factor,
and that it can be associated with improved functions. In addi-
tion, it has been suggested that angiogenesis links external stimuli
including exercise or learning to neurogenesis (Jin et al., 2002;
Cao et al., 2004; van Praag et al., 2005; Udo et al., 2008).
We obtained no evidence for changes in numbers ormorpho-
logical phenotypes of Iba1 microglia or in the expression of
CD11b after 3.5 months of A immunotherapy. This finding
raises the possibility that microglia were either not activated fur-
ther over levels in non-tg controls or that they were only tran-
siently activated during immunotherapy and have returned to
levels of control-treated transgenic mice after 3.5 months of treat-
ment as described previously (Wilcock et al., 2004b; Dickstein et al.,
2006). The fact that there were no significant changes in plasma
A42in-A-treatedmicearguesagainst a significant roleofperiph-
eral A sink in our experiments (DeMattos et al., 2001).
The mechanism linking A-related toxicity to impaired neu-
rogenesis and to defective morphology of newly born neurons
identified in our experiments is unknown. A possible role for
PrPc in mediating A-related impairments of synaptic plasticity
involves PrPc functions as a cell surface receptor that binds oli-
gomeric A aggregates to a domain of PrPc that is associatedwith
neurodegeneration and with impaired hippocampal LTP in re-
sponse to A oligomer binding (Lauren et al., 2009). Interest-
ingly, we found that PrPc was present on the dendrites of newly
born neurons at approximately equal levels compared with pre-
existing brain cells, covering 5% of the dendritic surface of newly
born neurons. Dendritic PrPc had a patchy appearance consistent
with a possible presence of PrPc on dendritic spines of the newly
born neurons, whichmay explain the observed vulnerability of den-
dritic spines in our APP/PS1 mice as well as the recovery of spine
density and dendritic morphology during A immunotherapy.
In conclusion, our study shows that passive A immunotherapy
can restore hippocampal neurogenesis inAPP/PS1-transgenicmice.
In particular, A immunotherapy rescued the length and arboriza-
tion of dendrites of newly born neurons and restored the density of
mushroom and long-thin spines. The newly born neurons showed
signs of functional activity indicated by expression of the immediate
early gene Zif268 in BrdU/NeuN cells. A immunotherapy in-
creased the numbers of SYN-positive boutons, and it increased an-
giogenesis in APP/PS1micewith pre-existing-amyloid pathology.
The presence of PrPc on the dendrites ofGFPnewly bornneurons
provides suggestive evidence that itmaymediateA-related toxicity
in these cells. The rescuedneurogenesis andmorphological develop-
ment of the newly born neurons constitute a novel mechanism that
could explain part of the functional improvements during passive
A immunotherapy. Our findings provide the first evidence that
antibody-related stimulation of endogenous stem cells and the de-
velopment of their progeny,mediated through clearance or neutral-
ization of the pathological microenvironment, may become a new
therapeutic strategy for the rehabilitationof functions compromised
by the toxicity of A-related peptides in AD.
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